Observational studyJournal of the American Heart Association2026
Impact of Combined Anticoagulant and Antiplatelet Therapy in Older Patients With Atrial Fibrillation: ANAFIE Subanalysis.
Observational study in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to evaluate the impact of concomitant use of oral anticoagulants (OAC) and antiplatelet drugs (APD) on clinical outcomes compared with OAC monotherapy in patients aged ≥75 years with atrial fibrillation.
methodsThe ANAFIE (All Nippon AF [Atrial Fibrillation] in Elderly) Registry was a prospective multicenter observational study in Japan. This subanalysis included patients aged ≥75 years with nonvalvular atrial fibrillation receiving OAC. Patients were classified into OAC monotherapy and concomitant OAC+APD therapy groups. Clinical outcomes, including stroke/systemic embolism, major bleeding, and all-cause mortality, were compared using Cox proportional hazards models. Within the OAC+APD group, outcomes were also compared between patients using direct OACs and those using warfarin.
resultsAmong 29 818 patients (median age 81 years, 42.3% female), 4861 (16.3%) received OAC+APD therapy. This group had higher proportion of men, previous cerebrovascular disease, and previous myocardial infarction. The group showed increased risk of cardiovascular death [1.57 versus 0.94/100 person-years, adjusted hazard ratio (aHR), 1.29 [95% CI, 1.01-1.64]. There were no significant differences in stroke/systemic embolism, major bleeding, or all-cause mortality. Within the OAC+APD group, direct OAC use was associated with lower risks of stroke/systemic embolism (aHR, 0.55 [95% CI, 0.38-0.80]), intracranial hemorrhage (aHR, 0.52 [95% CI, 0.30-0.90]), and all-cause mortality (aHR, 0.73 [95% CI, 0.58-0.91]) compared with warfarin.
conclusionsIn older patients with atrial fibrillation, OAC+APD therapy was associated with higher incidence of cardiovascular death than OAC monotherapy, without significant differences in other clinical outcomes. For patients requiring combination therapy, DOACs may be preferable to warfarin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.